Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

5149 - Circulating and tumor-associated caspase-4: a novel diagnostic and prognostic biomarker for Non-Small Cell Lung Cancer patients?

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Rosalinda Sorrentino

Citation

Annals of Oncology (2018) 29 (suppl_8): viii14-viii57. 10.1093/annonc/mdy269

Authors

R. Sorrentino1, M. Terlizzi2, C. Colarusso1, A. Saccomanno1, R. Salvi3, R.P. Aquino1, A. Pinto1

Author affiliations

  • 1 Department Of Pharmacy, University of Salerno, 84084 - Fisciano/IT
  • 2 Dpt Of Pharmacy, University of Salerno, 84084 - Fisciano/IT
  • 3 Thoracic Surgery Unit, AORN, Monaldi, 80131 - Naples/IT
More

Resources

Abstract 5149

Background

Late diagnosis limits therapeutic options and survival rate of non-small cell lung cancer (NSCLC) patients. Therefore, the identification of biomarkers represents an emerging medical need.

Methods

A highly sensitive and specific ELISA test was developed to identify/quantify a novel/selective diagnostic biomarker for NSCLC patients, caspase-4, which was detected into the plasma and tissues of NSCLC patients. This test was validated by using plasma from 125 NSCLC patients and 79 healthy (non-pathological) subjects. Caspase-4 quantification was also assessed in the lung tumor mass of 98 paired-matched NSCLC patients compared to 10 non-tumor lung tissues (i.e. tuberculosis).

Results

Circulating caspase-4 was detected in both healthy and NSCLC patients; however, at different range values: 2.603-3.372 ng/ml for NSCLC patients (95% CI) compared to 0.3994-0.6219 ng/ml for healthy subjects (95% CI). The sensitivity of the test ranged from 97.07% to 100%; the specificity was 88.1% with a positive predictive value of 92.54%, accuracy of 95.19% and AUC of 0.971. Tissue levels of caspase-4 in the tumor mass showed that 72 (72.7%) out of 99 patients were positive. More importantly, higher levels (cut-off value= 0.307 ng/ml) of caspase-4 in the tumor mass were associated to reduced overall survival (median 0.92 years) compared to NSCLC patients with lower levels (median 3.02 years).

Conclusions

We report for the first time caspase-4 as a novel diagnostic and prognostic biomarker, opening new therapeutic perspectives for NSCLC patients.

Clinical trial identification

Legal entity responsible for the study

ImmunePharma srl.

Funding

Invitalia-Italian Ministry of Economy (MISE).

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings